Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.49 |
| ▸ | HTR1A | P08908 | 5/20 | 0.49 |
| ▸ | HTR2A | P28223 | 5/20 | 0.49 |
| ▸ | HTR7 | P34969 | 5/20 | 0.49 |
| ▸ | DRD3 | P35462 | 5/20 | 0.49 |
| ▸ | DRD2 | P14416 | 4/20 | 0.49 |
| ▸ | HTR2C | P28335 | 4/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | HTR2B | P41595 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577968 | 0.89 | MCHR1 (0.61) | ACHEMCHR1HTR1AHTR2AHTR7 | |
| Hydrochloric Acid SCHEMBL5578139 | 0.88 | MCHR1 (0.60) | ACHEMCHR1HTR1AHTR2AHTR7 | |
| Trifluoroacetic Acid SCHEMBL6807242 | 0.83 | MCHR1 (0.57) | ACHEMCHR1HTR1AHTR2AHTR7 | |
| SCHEMBL6915567 | 0.81 | DRD3 (0.58) | ACHEMCHR1HTR1AHTR2AHTR7 | |
| SCHEMBL6917619 | 0.81 | ACHE (0.61) | ACHEMCHR1HTR1AHTR2AHTR7 | |
| SCHEMBL6916872 | 0.80 | ACHE (0.60) | ACHEMCHR1HTR1AHTR2AHTR7 | |
| SCHEMBL6914762 | 0.79 | ACHE (0.54) | ACHEMCHR1HTR1AHTR2AHTR7 | |
| SCHEMBL6918983 | 0.76 | ACHE (0.71) | ACHEMCHR1 | |
| SCHEMBL6914709 | 0.75 | ACHE (0.52) | ACHEMCHR1HTR1AHTR2AHTR7 | |
| SCHEMBL7065256 | 0.74 | TSHR (0.48) | ACHEMCHR1HTR1AHTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063699-A1 | Gpr14 antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1310490-A1 | GPR14 ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063699-A1 | Gpr14 antagonist | GPR142, GPR139, GPR4 | ACHE 4719/4885MCHR1 191/4885HTR1A 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.